← Browse by Condition
Medical Condition

migraine

Total Trials
12
Recruiting Now
12
Trial Phases
Phase 3

Migraine is a debilitating neurological condition affecting approximately 1 billion people globally, ranking as the second leading cause of disability worldwide by years lived with disability. Clinical trials have transformed acute and preventive treatment, with the CGRP pathway now the most actively targeted mechanism — producing anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and oral CGRP receptor antagonists (rimegepant, ubrogepant, atogepant) as approved agents, with numerous successors in trials.

Current trials investigate next-generation anti-CGRP agents with extended dosing intervals, combination preventive strategies for high-frequency migraine, valrocemide and Nav1.7 inhibitors for treatment-resistant patients, and non-pharmacological approaches including non-invasive vagus nerve stimulation (nVNS), TMS devices, and digital therapeutics. Trials also address cluster headache, chronic migraine, and vestibular migraine as distinct entities.

Migraine frequency (episodic: <15 headache days/month; chronic: ≥15/month) and medication overuse history are key eligibility criteria; biomarker-based enrichment trials use CGRP blood levels.

Frequently Asked Questions — migraine Clinical Trials

How many clinical trials are currently recruiting for migraine?
ClinicalMetric currently tracks 12 actively recruiting clinical trials for migraine, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 12. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for migraine?
migraine research spans Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a migraine clinical trial?
Eligibility criteria for migraine trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 3
1
Top Sponsors
Riphah International University 1 trial
Danish Headache Center 1 trial
Beijing Tiantan Hospital 1 trial
Peking University Third Hospital 1 trial
Cerenovus, Part of DePuy Synthes Products, Inc. 1 trial

Recruiting Clinical Trials

NCT06504537
Recruiting

Comparative Effects of Theragun Percussion Therapy and Compression Therapy in The Patients With Migraine

Enrollment
50 pts
Location
Pakistan
Sponsor
Riphah International Universit...
View Trial →
NCT06959004
Recruiting

Substance P-Induced Migraine Attacks Without Aura

Enrollment
21 pts
Location
Denmark
Sponsor
Danish Headache Center
View Trial →
NCT05334927
Recruiting

China HeadAche DIsorders RegiStry

Enrollment
10,000 pts
Location
China
Sponsor
Beijing Tiantan Hospital
View Trial →
NCT06953622
Recruiting

Establishment of a Clinical and Prognostic Follow-up Cohort of Migraine Patients With Patent Foramen Ovale

Enrollment
330 pts
Location
China
Sponsor
Peking University Third Hospit...
View Trial →
NCT06735833
Recruiting

MMA Embolization for Refractory Chronic Migraine

Enrollment
70 pts
Location
United States
Sponsor
Cerenovus, Part of DePuy Synth...
View Trial →
NCT06150781
Recruiting

Aimovig Pregnancy Exposure Registry

Enrollment
2,842 pts
Location
United States
Sponsor
Amgen
View Trial →
NCT07279623
Recruiting

Intra-Nasal Mechanical Stimulation (INMEST) as a Potential Preventative Treatment for Migraine

Enrollment
110 pts
Location
Sweden
Sponsor
Abilion Medical Systems AB
View Trial →
NCT05156398 Phase 3
Recruiting

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Enrollment
640 pts
Location
United States, Canad...
Sponsor
Pfizer
View Trial →
NCT07454798
Recruiting

A Feasibility Trial of Virtual Reality Neurofeedback for Adolescents With Migraine

Enrollment
38 pts
Location
United States
Sponsor
Children's Mercy Hospital Kans...
View Trial →
NCT06808230
Recruiting

Cocoa Extract for Migraine Trial

Enrollment
114 pts
Location
United States
Sponsor
Brigham and Women's Hospital
View Trial →
NCT07159750
Recruiting

Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

Enrollment
700 pts
Location
United States, Argen...
Sponsor
Hospital Universitari Vall d'H...
View Trial →
NCT07029126
Recruiting

Improving the Perception of Stress and Mutuality in Caregivers (MI-DEAR Study) of Migraine Patients With Depressive Symptoms Treated With Fremanezumab: A Study to Evaluate Whether Fremanezumab Reduces the Impact on Caregivers and Increases Couple Reciprocity

Enrollment
300 pts
Location
Italy
Sponsor
Fondazione Policlinico Univers...
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology